Therefore, combination of ICB with other immune-activating strategies, such as DDRi, might be a promising approach to overcome ICB resistance in cancer patients who are PD-L1-negative or PD-L1 positive but acquire resistance to ICB. The gene discussed is CD274; the disease is cancer.